One Broadway, 14th Floor
124 articles with X4 Pharmaceuticals
X4 Pharmaceuticals to Present Clinical Data Used to Determine Phase 3 Dose from Phase 2/3 Study of X4P-001-RD in WHIM Syndrome
Study designed to evaluate X4P-001-RD in a rare genetic, primary immunodeficiency disease to be presented at the American Society of Hematology meeting
X4 Pharmaceuticals Presents Clinical Data Showing Combination of X4P-001 and Opdivo® (nivolumab) Improved Clinical Responses in RCC Patients Unresponsive to Opdivo Monotherapy
Findings with combination therapy of anti-PD-1 and CXCR4 antagonist in patients with clear cell renal cell carcinoma (ccRCC) presented in Poster Discussion session at ESMO 2018
X4 Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for X4P-001-RD for the Treatment of WHIM Syndrome
X4 Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s drug candidate, X4P-001-RD for the treatment of WHIM syndrome
X4 Pharmaceuticals and Collaborators Present Data that WHIM Syndrome is Underdiagnosed and Patients are Impacted by Broad Spectrum of Medical Complications
Three poster presentations showcased at NORD Rare Disease Summit
Data to highlight X4P-001-IO, orally bioavailable CXCR4 antagonist, in advanced renal cell carcinoma and melanoma
10/1/2018Here's a look at who shook things up in the world of pharma and biotech this week.
Mr. Wyzga brings leadership experience, including in rare diseases and cancer
X4 Presents Data from Ongoing Phase 2 Study Demonstrating Promising Activity of X4P-001-RD in Patients with WHIM Syndrome
Dose dependent increases in absolute neutrophil and lymphocyte counts observed in all patients treated with X4P-001-RD
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
X4 Pharmaceuticals Reports Positive Clinical Data from Phase 2 Expansion Study of X4P-001-IO and Axitinib in Patients with Clear Cell Renal Cell Carcinoma
X4 Pharmaceuticals announced positive clinical results from the Phase 2 expansion of an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta® (axitinib) in patients with clear cell renal cell carcinoma (ccRCC).
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
X4 Pharmaceuticals will present clinical data highlighting their Phase II X4P-001-RD drug.
X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with Clear Cell Renal Cell Carcinoma
X4 Pharmaceuticals, today announced results from a pilot study of X4P-001-IO in combination with Opdivo® (nivolumab) in patients with clear cell renal cell carcinoma (ccRCC).
X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo® (nivolumab)
Study designed to evaluate X4P-001-IO in expanded range of combination treatment settings to be presented at the Annual Meeting of the Association for Cancer Immunotherapy
Jeffrey Modell Foundation and X4 Pharmaceuticals to Sponsor First Genetic Screening Study for Patients with WHIM Syndrome
Study aims to establish a genetic screening approach to aid in diagnosis of patients with WHIM syndrome
X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity
Clinical data demonstrate single agent X4P-001-IO increases immune cell infiltration and activation in the tumor microenvironment (TME)
X4 Pharmaceuticals to Report Clinical Biomarker Data with X4P-001 at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001, the Company’s CXCR4 antagonist, has been selected for presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL.
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Paula Ragan, PhD, President and Chief Executive Officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Wednesday, March 14, 2018, at 8:00 a.m. Eastern time.
First Clinical Data for X4P-001-RD Demonstrated Promising Activity in Patients With WHIM Syndrome, a Primary Immunodeficiency Disease
The preliminary results from the study demonstrated promising activity with dose-dependent increases in neutrophil and lymphocyte counts in patients with WHIM syndrome.
X4 Pharma: First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients With WHIM Syndrome will be Presented at American Society for Hematology Annual Meeting
Dr. David C. Dale, MD will present the first clinical data from an on-going study of X4P-001-RD in patients with WHIM Syndrome.